{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:15:25Z","timestamp":1760238925630,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["220A480014"],"award-info":[{"award-number":["220A480014"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>This study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (n = 13) with cancer who had been administered olanzapine as an anti-emetic drug (AED) during a high and moderate emetogenic chemotherapy block from January 2018 to March 2020. Patients were administered other prophylactic AEDs according to practice guidelines. The mean age of the patients was 14.1 \u00b1 5.5 years. The total number of chemotherapy cycles was 41. Twenty-one (51.2%) chemotherapy blocks were high emetogenic chemotherapy and 20 (48.8%) blocks were moderate emetogenic chemotherapy. Olanzapine was used for prophylaxis in 20 (48.8%) blocks of chemotherapy and rescue in 21 (51.2%). Of the 41 cycles, a complete response to olanzapine was achieved in 31 (75.6%), partial response in 6 (14.6%), and no response in 4 (9.8%). The mean dose was 0.07 \u00b1 0.04 mg\/kg\/dose and 2.50 \u00b1 1.37 mg\/m2\/dose. Adverse effects included somnolence, hyperglycemia, fatigue, and disturbed sleep. Our findings indicate that olanzapine was effective and safe for treating chemotherapy-induced nausea and vomiting in children. A prospective controlled study is needed to confirm these findings.<\/jats:p>","DOI":"10.3390\/children7090140","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T20:44:13Z","timestamp":1600289053000},"page":"140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children"],"prefix":"10.3390","volume":"7","author":[{"given":"So Rae","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Young","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1051","authenticated-orcid":false,"given":"Jae Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, Yeungnam University, Daegu 42415, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00520-017-3864-8","article-title":"Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: A multi-center, feasibility study","volume":"26","author":"Flank","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pbc.25286","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review","volume":"62","author":"Flank","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","article-title":"Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis","volume":"56","author":"Pagsberg","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1517\/14656566.9.3.467","article-title":"Olanzapine for the treatment of bipolar disorder in children and adolescents","volume":"9","author":"Strawn","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40264-014-0219-y","article-title":"The safety of olanzapine in young children: A systematic review and meta-analysis","volume":"37","author":"Flank","year":"2014","journal-title":"Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4143\/crt.2017.577","article-title":"A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study","volume":"51","author":"Jeon","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_10","first-page":"1","article-title":"Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal","volume":"5","author":"Dulal","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12032-017-1074-3","article-title":"Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy","volume":"35","author":"Mehra","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","article-title":"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study","volume":"15","author":"Navari","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","article-title":"A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study","volume":"13","author":"Navari","year":"2005","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e28532","DOI":"10.1002\/pbc.28532","article-title":"Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial","volume":"67","author":"Radhakrishnan","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e27646","DOI":"10.1002\/pbc.27646","article-title":"Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline","volume":"66","author":"Robinson","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.23114","article-title":"Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients","volume":"57","author":"Dupuis","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","article-title":"Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients","volume":"60","author":"Dupuis","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_20","first-page":"164","article-title":"Erdheim-Chester disease: Symmetric uptake in the (99m)Tc-MDP bone scan","volume":"11","author":"Zanglis","year":"2008","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J. Support Oncol."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/7\/9\/140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:10:39Z","timestamp":1760177439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/7\/9\/140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["children7090140"],"URL":"https:\/\/doi.org\/10.3390\/children7090140","relation":{},"ISSN":["2227-9067"],"issn-type":[{"type":"electronic","value":"2227-9067"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}